Free Newsletter
BMS, Repligen settle Orencia fight
Four companies, two disputed patents, two multimillion-dollar settlements.
Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject to a patent dispute between the two companies. Bristol-Myers will pay $5 million plus royalties on U.S. net sales of Orencia to settle the disagreement. Repligen expects its first years' receipts from BMS to be around $30 million.
Meanwhile, Depomed will get about $10 million in payments and royalties in settlement of a patent infringement case against Ivax Corp. and its parent company, Teva Pharmaceuticals. The drug in question was the diabetes treatment Glucophage XR.
- check out the Orencia agreement
- see the Depomed news in the San Jose Business Journal
Related Articles:
NICE snubs Orencia, picks 3 rivals. Report
Regulatory panel gives BMS' Orencia unanimous approval. Report
More stories about Teva Pharmaceutical rheumatoid arthritis Repligen Orencia Depomed Bristol-Myers Squibb
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: